Obesity Clinical Trial
Official title:
Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors-Renewal
Verified date | January 2024 |
Source | Temple University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Enhancing children's sleep may be a novel approach for prevention of obesity and cardiovascular (CV) disturbance. Observational studies with children demonstrate that short sleep increases risk of obesity and other CV risk factors. Randomized controlled trials with children 8-11 years old demonstrate that enhancing sleep duration leads to positive changes in eating and activity behaviors and weight status, particularly for children who enhance their sleep the most. Enhancing sleep may be particularly important for racial minority children and those from lower socioeconomic backgrounds given their increased risk for short sleep, obesity and CV risk factors. In this study two active obesity preventive interventions will be evaluated: a) enhancing sleep alone (Optimize Sleep [OS]), and b) enhancing sleep along with eating and activity behaviors that have demonstrated efficacy for obesity prevention and are implicated in self-regulatory pathways related to sleep (i.e., energy dense snack foods and beverages, TV viewing, and physical activity) (OS-Plus). Two hundred four children 6-11 years old who are primarily African American/black, primarily from low socioeconomic backgrounds, and who sleep < 9.5 hours/night into a 12-month study will be enrolled. Children will be randomly assigned to either OS or OS-Plus. Over the 6-month treatment phase, all children will attend an 8-session treatment; monthly phone contacts will occur during maintenance (6-12 months). Primary aim is to determine the efficacy of OS-Plus relative to OS on change in body mass index z-score (BMIz) at end of treatment. Secondary aims will assess efficacy of OS-Plus relative to OS on additional cardiometabolic risk factors, eating and activity behaviors. Exploratory aims will assess maintenance of effects at 12 months.
Status | Completed |
Enrollment | 149 |
Est. completion date | September 30, 2023 |
Est. primary completion date | January 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 11 Years |
Eligibility | Inclusion Criteria: 1. Caregiver-reported child age of 6-11 years 2. < 9.5 Hours time-in-bed for sleep most days/week 3. BMI for age and gender > 25th percentile (but no greater than 100% overweight) 4. Understanding of and ability to complete protocol 5. Self-reported caregiver age of 18 years and primary caregiver at bedtimes/wake times 6. Likes food used in the eating regulation paradigms 7. Willingness to be randomized to either treatment condition. Exclusion Criteria: 1. Diagnosable sleep disorder 2. Medication use or diagnosis of medical or psychiatric condition that may impact sleep/weight status 3. Current or planned treatment for weight control 4. Allergies or dietary restrictions that would prevent consumption of foods used in the study |
Country | Name | City | State |
---|---|---|---|
United States | Temple University | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Temple University | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in BMIz | change in body mass index z-score (accounting for child age and sex) | Change from baseline BMIz at 6 months | |
Secondary | Change in Body Composition | change in body composition (% body fat) will be estimated by air displacement plethysmography (BOD POD®; Life Measurement Instruments, Concord, CA) | Change from baseline percent body fat at 6 months | |
Secondary | Change in Waist Circumference | Change in measured waist circumference | Change from baseline waist circumference at 6 months | |
Secondary | Change in Insulin Resistance | Change in the homeostatic model assessment of insulin resistance (HOMA-IR) | Change from baseline HOMA-IR at 6 months | |
Secondary | Change in Blood Glucose Levels | 2-hour blood glucose levels measured within the context of an oral glucose tolerance test | Change from baseline blood glucose levels at 6 months | |
Secondary | Change in Non-HDL cholesterol (non-HDL-C) | Total cholesterol (TC) minus HDL-C, includes LDL-C, VLDL-C, and atherogenic apo-B containing lipoproteins | Change from baseline in Non-HDL-C at 6 months | |
Secondary | Change in Insulin Sensitivity Index (ISI) | Insulin Sensitivity Index measured within the context of an oral glucose tolerance test | Change from baseline ISI at 6 months | |
Secondary | Change in Sleep Period | Wrist-worn actigraphy | Change from baseline in the sleep period at 6 months | |
Secondary | Change in Caloric Intake | 24-hr dietary recalls on two days used to estimate caloric intake | Change from baseline in caloric intake at 6 months | |
Secondary | Change in Food Reinforcement | Measured using a validated computer activity (Behavioral Choice Task), which assesses motivation for a food reward | Change from baseline in food reinforcement at 6 months | |
Secondary | Change in Eating in the Absence of Hunger (EAH) | Food consumed within the context of the eating in the absence of hunger paradigm | Change from baseline in EAH at 6 months | |
Secondary | Change in Percent Time spent in Moderate to Vigorous Physical Activity (MVPA) | Waist-worn accelerometer | Change from baseline in MVPA at 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |